Rallybio 2026: Revenue $0 Net income ($2.73M), EPS ($0.48) — 10-Q Summary
Rallybio reported no revenue and a net loss of $2.73M in 2026, compared to $212K revenue and $16.02M net income in the prior year. The company agreed to merge with Avenzo, with investors providing $215M pre-merger. Rallybio also announced progress in its Phase 1 study of RLYB116.
How this was made
The 30-second read
Why it matters
The earnings miss and merger news create short‑term downside risk, but the capital injection may support future R&D and a possible valuation boost if the transaction closes.
Market read
Micro‑cap biotech investors will weigh the earnings disappointment against the merger financing.
What to watch
Potential pre‑money valuation uplift from Avenzo investors and any upcoming clinical data releases.
Background
Rallybio is a clinical‑stage biotech that reported a quarterly loss and zero revenue while announcing a merger with Avenzo, which is providing significant cash support.
Ticker impact
Rallybio filed its 10‑Q showing zero revenue, a $2.73 M loss and a pending merger with Avenzo funded by $215 M.
likely downward pressure as the market prices in the earnings miss and merger uncertainty
Earnings miss and no revenue are bearish for a micro‑cap; however, the $215 M cash infusion for the merger could mitigate downside if the deal closes.
Market effects
Highlights challenges for small biotech firms with no revenue and reliance on merger financing.
Limited to U.S. biotech micro‑cap segment.
Minimal; no broader market or macro impact.
Counterpoint
If the merger proceeds, the cash infusion could fund rapid development, offering upside beyond the earnings miss.
Key entities
- companyRallybio Corp
Biotech issuer reporting the 10‑Q.
- companyAvenzo
Merger partner providing $215 M financing.